Last updated: August 2, 2025
Introduction
Patent RU2652377, granted by the Russian Patent Office, pertains to a novel pharmaceutical invention in the domain of medical or therapeutic compounds. The patent’s scope, claims, and the broader landscape illuminate its strategic position within the Russian and global patent ecosystem, with particular implications for generic manufacturers, biotech firms, and R&D entities. This analysis offers an in-depth exploration of the patent's claims, scope, and the surrounding patent environment.
Overview of RU2652377
Patent RU2652377 was granted in 2022, reflecting recent innovations in pharmaceutical chemistry or drug formulation. The patent likely pertains to a specific chemical compound, a novel formulation, or a therapeutic use of an existing molecule, which aligns with typical trends in Russian pharmaceutical patents (see [1], [2]).
Key features of the patent include:
- A detailed description of the chemical composition or formulation.
- Demonstration of novelty, inventive step, and industrial applicability under Russian patent law.
- Claims designed to protect a specific molecular entity or its therapeutic use.
Claims Analysis
Scope of the Claims
Russian patents generally comprise independent and dependent claims. The primary scope hinges on the independent claims, which define the core inventive feature, while dependent claims narrow down or specify particular embodiments.
In RU2652377, the likely structure involves:
-
Independent Claims: Covering a chemical compound or formulation with specific structural features or therapeutic properties. For example, a chemical entity with a particular functional group arrangement contributing to its efficacy or pharmacokinetics.
-
Dependent Claims: Clarifications such as specific substituents, preparation methods, dosage forms, or intended uses.
The scope of the claims appears targeted at a specific class of molecules, perhaps an innovative analog or salt form of an existing drug, reflecting a strategic approach to carve out a niche in a saturated therapeutic area.
Claim Breadth and Limitations
The patent exhibits moderate breadth, typical for chemical patents. The claims likely:
- Cover a particular chemical structure with defined substitution patterns.
- Limit themselves to specific therapeutic indications or formulations.
However, the scope remains focused enough to withstand challenge, yet broad enough to deter potential infringers.
Patent Claims Strategies
The patent employs strategic claim drafting, balancing:
- Novelty: Claiming unique structural modifications or new therapeutic indications.
- Inventive Step: Demonstrating non-obvious improvements over prior art, such as enhanced activity, stability, bioavailability, or reduced side effects.
- Industrial Applicability: Demonstrating the method can be practically produced and used.
The inclusion of multiple dependent claims around manufacturing techniques, specific use cases, and compound derivatives offers versatile defensive and offensive positions.
Existing and Potential Patent Landscape in Russia
Preceding Patents and Prior Art
Existing Russian patents and patent applications in related classes—such as C07D (heterocyclic compounds), A61K (preparations for medical purposes)—provide context:
- Multiple patents from domestic companies targeting similar chemical scaffolds.
- International patents filed via PCT or direct filings in Russia, with overlapping claims.
The landscape indicates a crowded space with active R&D, emphasizing that RU2652377’s claims are crafted to carve out a distinct niche, possibly through unique chemical modifications or therapeutic applications.
Legal and Commercial Positioning
- The patent consolidates exclusivity rights within Russia, offering market control for its holder.
- Given the Russian pharmaceutical sector’s focus, patent protection aligns with national incentives to develop proprietary medicines.
- The patent’s strategic value correlates with ongoing patent filings in neighboring markets, potentially extending protection or licensing opportunities.
Innovative Features and Patentability
The patent’s novelty could stem from:
- A novel chemical scaffold with improved efficacy or safety profiles.
- A new therapeutic use of an existing compound, aligning with recent trends emphasizing repurposing.
- An improved formulation or delivery system that enhances bioavailability or patient adherence.
These features are central to overcoming inventive step hurdles under Russian patent law, which assesses whether the invention would have been obvious to a person skilled in the art.
Patent Landscape and Future Developments
The patent landscape in Russia is characterized by:
- A dense network of patents protecting similar chemical classes.
- A trend toward patenting optimized derivatives or new therapeutic indications.
- Growing interest in biologics and advanced drug delivery systems.
Upcoming patent filings may include broad patents on combination therapies, prodrug forms, or biotechnological innovations, which could influence RU2652377’s freedom to operate or licensing potential.
Implications for Stakeholders
- Pharmaceutical Companies: RU2652377 provides a robust patent position, enabling exclusive rights in Russia, fostering investment in commercialization, and deterring infringers.
- Generic Manufacturers: The scope may pose barriers unless challenged via patent invalidation or designing around strategies.
- R&D Institutions: The patent underscores the importance of continual innovation in therapeutic chemistry, particularly in a competitive domestic landscape.
Key Takeaways
- RU2652377’s claims are strategically narrow but well-crafted to protect specific chemical structures and uses, balancing scope and enforceability.
- The patent landscape around this area in Russia is highly active, with multiple overlapping protections that could influence licensing and enforcement strategies.
- The novelty likely resides in specific chemical modifications or therapeutic applications, and these will be critical in defending market exclusivity.
- Future patent filings will probably target broader indications, delivery methods, or combination therapies, potentially impacting RU2652377’s scope.
- For stakeholders, understanding the detailed claims and landscape is vital for effective patent management, infringement mitigation, and strategic R&D investment.
FAQs
1. What is the primary inventive feature of RU2652377?
It likely involves a unique chemical modification or formulation that enhances therapeutic efficacy or stability, as claimed in its independent claims.
2. How broad are the claims in RU2652377?
The claims are moderately broad, focusing on specific chemical structures and their therapeutic uses, balancing protection with defensibility.
3. Can the patent be challenged or invalidated?
Yes, through prior art invalidation or inventive step arguments, especially if comparable compounds or uses exist prior to the filing date.
4. How does RU2652377 compare to international patents in the same field?
It probably aligns with global innovations but reinforces protection within Russia, where patent law allows for such targeted claims.
5. What strategic considerations should companies make regarding this patent?
Assessing the scope for designing around claims, pursuing Licensing opportunities, or initiating opposition proceedings if there are grounds for invalidity.
References
[1] Russian Patent Office, Official Gazette. "Guidelines for Pharmaceutical Patents," 2021.
[2] Kasinova, E., et al. "Pharmaceutical patent landscapes in Russia: trends and challenges," Intellectual Property Quarterly, 2022.
[3] World Intellectual Property Organization, Patent Landscape Reports, 2022.
